Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.077 | 0.007 |
mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.092 | 0.007 |
mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.088 | 0.007 |
mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.008 |
mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.09 | 0.008 |
mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.49 | 0.008 |
mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.088 | 0.008 |
mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.009 |
mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.009 |
mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.009 |